Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis B Cortot

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|April 5, 2017
Exon 14 Deleted MET Receptor as a New Biomarker and Target in CancersAlexis B Cortot, Zoulika Kherrouche, Clotilde Descarpentries, et al.
Oncogene|March 20, 2018
The multiple paths towards MET receptor addiction in cancerLeslie Duplaquet, Zoulika Kherrouche, Simon Baldacci, et al.
ESMO Open|September 21, 2018
Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysisNicolas Girard, Delphine Cozzone, Lucie de Leotoing, et al.
Lung Cancer (Amsterdam, Netherlands)|March 2, 2020
Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancerBenjamin Besse, Pilar Garrido, Alexis B Cortot, et al.
Clinical Lung Cancer|July 14, 2023
MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and OutcomesJulien Mazieres, Helene Vioix, Boris M Pfeiffer, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2013
Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective studyStéfanie Habib, Julie Delourme, Xavier Dhalluin, et al.
Clinical Lung Cancer|September 22, 2021
A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 MutationFrançois Pinquie, Alexis B Cortot, Louise-Marie Chevalier, et al.
Clinical Lung Cancer|August 16, 2018
Current and Former Smokers: Who Wants To Be Screened?Sébastien Couraud, Laurent Greillier, Lysel Brignoli-Guibaudet, et al.
Current Oncology Reports|March 7, 2018
Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine DependenceLaurent Greillier, Alexis B Cortot, Jérôme Viguier, et al.
Future Oncology (London, England)|May 6, 2025
Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancerAntonio Passaro, Alexis B Cortot, Ryan D Gentzler, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|April 5, 2017
Exon 14 Deleted MET Receptor as a New Biomarker and Target in CancersAlexis B Cortot, Zoulika Kherrouche, Clotilde Descarpentries, et al.
Oncogene|March 20, 2018
The multiple paths towards MET receptor addiction in cancerLeslie Duplaquet, Zoulika Kherrouche, Simon Baldacci, et al.
ESMO Open|September 21, 2018
Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysisNicolas Girard, Delphine Cozzone, Lucie de Leotoing, et al.
Lung Cancer (Amsterdam, Netherlands)|March 2, 2020
Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancerBenjamin Besse, Pilar Garrido, Alexis B Cortot, et al.
Clinical Lung Cancer|July 14, 2023
MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and OutcomesJulien Mazieres, Helene Vioix, Boris M Pfeiffer, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2013
Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective studyStéfanie Habib, Julie Delourme, Xavier Dhalluin, et al.
Clinical Lung Cancer|September 22, 2021
A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 MutationFrançois Pinquie, Alexis B Cortot, Louise-Marie Chevalier, et al.
Clinical Lung Cancer|August 16, 2018
Current and Former Smokers: Who Wants To Be Screened?Sébastien Couraud, Laurent Greillier, Lysel Brignoli-Guibaudet, et al.
Current Oncology Reports|March 7, 2018
Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine DependenceLaurent Greillier, Alexis B Cortot, Jérôme Viguier, et al.
Future Oncology (London, England)|May 6, 2025
Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancerAntonio Passaro, Alexis B Cortot, Ryan D Gentzler, et al.
Pageof 8